⌕
Harmony Biosciences Holdings · HRMY · Nasdaq
Tenet 81 · Strong
Compare
$33.01+0.15%At closeTenet 81 · Strong
$33.01+0.05 (+0.15%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Harmony Biosciences Holdings (HRMY) Stock

Harmony Biosciences Holdings (HRMY) closed at $33.01 on Nov 17, 2026; its Tenet Score is 81 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

8 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$33.01
Nov 17, 2026
Market cap
$1.9B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
11.2×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
52-week range
25.90 – 43.49
low → high · as of close, Nov 16, 2026
Tenet Score
81/100
Strong · 340 Healthcare peers

Industry: Drugs

Harmony Biosciences Holdings Inc scores 81/100. Strong. Strongest on value and growth, trading at 11× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
81/ 100
Strong
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
92
Quality
73
Health
67
Growth
91

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueAQualityBHealthCGrowthAMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
1.8×
Sep 30, 2026 balance sheet
P/S
2.0×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
19%
TTM through Sep 30, 2026
Operating margin
24.0%
fiscal 2025, before interest and tax
Net margin
18.1%
TTM through Sep 30, 2026
Current ratio
3.44
Sep 30, 2026 balance sheet
Net debt / EBITDA
−2.6×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytim…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 143 US ETFs · top wrappers by weightSee all ETFs holding HRMY →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Harmony Biosciences Holdings in?

Harmony Biosciences Holdings is in the Healthcare sector and the Drugs industry.

What is Harmony Biosciences Holdings' Tenet Score?

Harmony Biosciences Holdings' Tenet Score is 81 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.